Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 12


ASCO GU 2023 interim analysis of MAGNITUDE, combination of niraparib and abiraterone acetate/prednisone in patients with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

  • 123456 Profile photo of Madelyn

    MAGTIDUTE study – niraparib + abiraterone in patients w/mCRPC and HRD mutations. Improvement in progression free survival…too early to know about overall survival benefit.